Rituxan and Venclexta – pro
The drug venetoclax is an oral inhibitor of BCL2, which regulates apoptosis has been approved as a single-agent treatment of relapsed or refractory chronic lymphocytic leukemia (r/r CLL) for patients who have the 17p deletion. A recent NEJM article concluded that among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab.
J.F. Seymour, VenetoclaxRituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.March 22, 2018 N Engl J Med 2018; 378:1107-1120
NCCN, CLL 2019